Proteomics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
Researchers from Newcastle University describe findings in arthritis
May 12th, 2008
According to a study from the United Kingdom, "Immunological tolerance in humans using anti-T-cell monoclonal antibodies (mAbs) may be hampered by a pro-inflammatory microenvironment. All clinical trials of such therapies in rheumatoid arthritis (RA), however, have selected patients with active disease at baseline." "Concurrent neutralization of inflammation with a TNF antagonist should maximize the potential of anti-T-cell mAbs to induce tolerance in RA. To evaluate the safety of combining a TNF antagonist and CD4 mAb in RA. An iterative pilot study focused on the safety of such combination therapy. Eight poor prognosis, seropositive RA patients were treated with combined...
Source: Proteomics Weekly (2008-05-12)
|
